Breast cancer research

​Much research is being done at the HUS Comprehensive Cancer Center to contribute to progress in cancer treatment and drug development. Below is a list of all ongoing trials in which you can volunteer to participate. An updated list of trials is also available on the Nordic NECT website.
 
 
How to become a clinical trial participant?
You can be referred to a clinical trial by your physician. You can also contact the clinical trial unit’s nurse manager directly and they can give you information on how to become a clinical trial participant, and help with finding a suitable trial if one is available.

Contact Information:
tel. +358 50 427 0680
 
 

Breast cancer, ongoing trials

  1. A Phase 3, randomized study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in the treatment of patients with HER2+ metastatic breast cancer, who have received two prior Anti-HER2 therapies and require systemic treatment
    The purpose of the study is to compare two therapies: margetuximab combined with cytostatic therapy, and trastuzumab combined with cytostatic therapy in patients with metastatic HER2-positive breast cancer who have received anti-HER2 treatment and require systemic therapy.

  2. A randomized phase III study comparing trastuzumap, pertuzumab plus docetaxel (TPD) followed by 3 cycles of chemotherapy  to the current standard regimen as the treatments of early HER2-positive breast cancer
    The purpose of the study is to compare the effectiveness and safety of two cytostatic regimens as adjuvant therapies for HER2-positive breast cancer. The purpose is to examine if short-term therapy containing trastuzumab, pertuzumab and docetaxel is better, equally good, or worse than traditional therapy in terms of effectiveness and side effects. The traditional therapy contains trastuzumab and docetaxel.

  3. A phase 1B study to evaluate safety anf clinical activity of pembrolozumab (MK-3475) in combination with chemotherapy as neoadjuvant treatment for trible negative breast cancer
    The purpose of the study is to assess the safety and effectiveness of the trial drug pembrolizumab (MK-3475) administered in combination with cytostatic therapy in pre-surgery treatment of triple-negative breast cancer.

  4. A Phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancr subjects with bone metastases treated with hormonal treatment background therapy
    The purpose of the study is to assess the effectiveness and safety of radium-223 dichloride in subjects diagnosed with human epidermal growth receptor 2 negative (HER2-negative), hormone receptor positive breast cancer accompanied by bone metastases and treated with background hormone therapy.

  5. COMPLEMEENT-1: An open label, multicenter, phase IIIb study to assess the safety anf efficacy of ribociclib (LEE001) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptorpositive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease
    The purpose of this study is to evaluate the safety and efficacy of ribociclib (LEE001) when used in combination with letrozole to treat hormone receptor positive (HR+) and HER2-negative (HER2-) advanced breast cancer in men and pre/postmenopausal women who have not received hormonal therapy for advanced breast cancer previously.